{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:11:52Z","timestamp":1777590712118,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,7,22]],"date-time":"2009-07-22T00:00:00Z","timestamp":1248220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s00259-009-1202-1","type":"journal-article","created":{"date-parts":[[2009,7,21]],"date-time":"2009-07-21T11:03:57Z","timestamp":1248174237000},"page":"3-11","source":"Crossref","is-referenced-by-count":43,"title":["Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson\u2019s disease who were diagnosed with dopamine PET"],"prefix":"10.1007","volume":"37","author":[{"given":"Kenji","family":"Ishibashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutomi","family":"Kanemaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiichi","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,7,22]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jnnp.67.2.189","volume":"67","author":"S Orimo","year":"1999","unstructured":"Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1999;67:189\u201394.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1202_CR2","first-page":"371","volume":"40","author":"A Satoh","year":"1999","unstructured":"Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, et al. Loss of 123I-MIBG uptake by the heart in Parkinson\u2019s disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999;40:371\u20135.","journal-title":"J Nucl Med"},{"key":"1202_CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s002590050544","volume":"27","author":"J Taki","year":"2000","unstructured":"Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson\u2019s disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med 2000;27:566\u201373.","journal-title":"Eur J Nucl Med"},{"key":"1202_CR4","first-page":"71","volume":"41","author":"H Takatsu","year":"2000","unstructured":"Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H, et al. Cardiac sympathetic denervation from the early stage of Parkinson\u2019s disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71\u20137.","journal-title":"J Nucl Med"},{"key":"1202_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jnnp.2004.037028","volume":"76","author":"H Nagayama","year":"2005","unstructured":"Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2005;76:249\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1202_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.74.4.423","volume":"74","author":"K Hamada","year":"2003","unstructured":"Hamada K, Hirayama M, Watanabe H, Kobayashi R, Ito H, Ieda T, et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2003;74:423\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1202_CR7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/WNL.53.5.1020","volume":"53","author":"S Braune","year":"1999","unstructured":"Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson\u2019s disease from multiple system atrophy. Neurology 1999;53:1020\u20135.","journal-title":"Neurology"},{"key":"1202_CR8","first-page":"1769","volume":"47","author":"DM Raffel","year":"2006","unstructured":"Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 2006;47:1769\u201377.","journal-title":"J Nucl Med"},{"key":"1202_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1017\/S0317167100031814","volume":"18","author":"AH Rajput","year":"1991","unstructured":"Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism\u2013a prospective study. Can J Neurol Sci 1991;18:275\u20138.","journal-title":"Can J Neurol Sci"},{"key":"1202_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1202_CR11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archneur.57.3.369","volume":"57","author":"J Jankovic","year":"2000","unstructured":"Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000;57:369\u201372.","journal-title":"Arch Neurol"},{"key":"1202_CR12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1212\/WNL.57.8.1497","volume":"57","author":"AJ Hughes","year":"2001","unstructured":"Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson\u2019s disease. Neurology 2001;57:1497\u20139.","journal-title":"Neurology"},{"key":"1202_CR13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00702-004-0208-x","volume":"112","author":"M Plotkin","year":"2005","unstructured":"Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005;112:677\u201392.","journal-title":"J Neural Transm"},{"key":"1202_CR14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/syn.10192","volume":"48","author":"E Nurmi","year":"2003","unstructured":"Nurmi E, Bergman J, Eskola O, Solin O, Vahlberg T, Sonninen P, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson\u2019s disease using [18F]CFT PET. Synapse 2003;48:109\u201315.","journal-title":"Synapse"},{"key":"1202_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.410340331","volume":"34","author":"JJ Frost","year":"1993","unstructured":"Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson\u2019s disease. Ann Neurol 1993;34:423\u201331.","journal-title":"Ann Neurol"},{"key":"1202_CR16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jnnp.67.6.737","volume":"67","author":"JO Rinne","year":"1999","unstructured":"Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1999;67:737\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1202_CR17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/WNL.44.7.1325","volume":"44","author":"A Antonini","year":"1994","unstructured":"Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson\u2019s disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325\u20139.","journal-title":"Neurology"},{"key":"1202_CR18","first-page":"65","volume":"41","author":"V Kaasinen","year":"2000","unstructured":"Kaasinen V, Ruottinen HM, N\u00e5gren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson\u2019s disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med 2000;41:65\u201370.","journal-title":"J Nucl Med"},{"key":"1202_CR19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.870080203","volume":"8","author":"JO Rinne","year":"1993","unstructured":"Rinne JO, Laihinen A, Rinne UK, N\u00e5gren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson\u2019s disease. Mov Disord 1993;8:134\u20138.","journal-title":"Mov Disord"},{"key":"1202_CR20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1531-8257(199911)14:6<1025::AID-MDS1020>3.0.CO;2-P","volume":"14","author":"C Dentresangle","year":"1999","unstructured":"Dentresangle C, Veyre L, Le Bars D, Pierre C, Lavenne F, Pollak P, et al. Striatal D2 dopamine receptor status in Parkinson\u2019s disease: an [18F]dopa and [11C]raclopride PET study. Mov Disord 1999;14:1025\u201330.","journal-title":"Mov Disord"},{"key":"1202_CR21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mds.870120107","volume":"12","author":"A Antonini","year":"1997","unstructured":"Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson\u2019s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997;12:33\u20138.","journal-title":"Mov Disord"},{"key":"1202_CR22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00415-006-0322-9","volume":"254","author":"J Wang","year":"2007","unstructured":"Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson\u2019s disease in various Hoehn & Yahr stages. J Neurol 2007;254:185\u201390.","journal-title":"J Neurol"},{"key":"1202_CR23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00259-004-1578-x","volume":"31","author":"GM Knudsen","year":"2004","unstructured":"Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson\u2019s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004;31:1631\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1202_CR24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10042","volume":"17","author":"YJ Kim","year":"2002","unstructured":"Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303\u201312.","journal-title":"Mov Disord"},{"key":"1202_CR25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00259-006-0258-4","volume":"34","author":"CC Verstappen","year":"2007","unstructured":"Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson\u2019s disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2007;34:502\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1202_CR26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF03165298","volume":"11","author":"T Fujiwara","year":"1997","unstructured":"Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann Nucl Med 1997;11:307\u201313.","journal-title":"Ann Nucl Med"},{"key":"1202_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/WNR.0b013e3282f3e3d8","volume":"19","author":"M Hashimoto","year":"2008","unstructured":"Hashimoto M, Kawasaki K, Suzuki M, Mitani K, Murayama S, Mishina M, et al. Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy. Neuroreport 2008;19:145\u201350.","journal-title":"Neuroreport"},{"key":"1202_CR28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/syn.20603","volume":"63","author":"K Ishibashi","year":"2009","unstructured":"Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 2009;63:282\u201390.","journal-title":"Synapse"},{"key":"1202_CR29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/(SICI)1099-1344(199912)42:12<1183::AID-JLCR274>3.0.CO;2-Z","volume":"42","author":"LO NK","year":"1999","unstructured":"NK LO, Dolle F, Lundkvist C, Sandell J, Swahn CG, Vaufrey F, et al. Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. J Labelled Compd Radiopharm 1999;42:1183\u201393.","journal-title":"J Labelled Compd Radiopharm"},{"key":"1202_CR30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02990030","volume":"17","author":"K Kawamura","year":"2003","unstructured":"Kawamura K, Oda K, Ishiwata K. Age-related changes of the [11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats: a PET study. Ann Nucl Med 2003;17:249\u201353.","journal-title":"Ann Nucl Med"},{"key":"1202_CR31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/archneur.1993.00540050026010","volume":"50","author":"A Antonini","year":"1993","unstructured":"Antonini A, Leenders KL, Reist H, Thomann R, Beer HF, Locher J. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch Neurol 1993;50:474\u201380.","journal-title":"Arch Neurol"},{"key":"1202_CR32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00006231-199405000-00003","volume":"15","author":"K Nakajima","year":"1994","unstructured":"Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994;15:317\u201323.","journal-title":"Nucl Med Commun"},{"key":"1202_CR33","first-page":"189","volume":"74","author":"S Gilman","year":"1998","unstructured":"Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189\u201392.","journal-title":"J Auton Nerv Syst"},{"key":"1202_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1\u20139.","journal-title":"Neurology"},{"key":"1202_CR35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ana.10236","volume":"52","author":"ST Li","year":"2002","unstructured":"Li ST, Dendi R, Holmes C, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson\u2019s disease. Ann Neurol 2002;52:220\u20133.","journal-title":"Ann Neurol"},{"key":"1202_CR36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02292766","volume":"11","author":"S Braune","year":"2001","unstructured":"Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001;11:351\u20135.","journal-title":"Clin Auton Res"},{"key":"1202_CR37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mds.20369","volume":"20","author":"J Spiegel","year":"2005","unstructured":"Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson\u2019s disease. Mov Disord 2005;20:552\u201361.","journal-title":"Mov Disord"},{"issue":"Pt 5","key":"1202_CR38","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283\u2013301.","journal-title":"Brain"},{"key":"1202_CR39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ana.410190510","volume":"19","author":"M Guttman","year":"1986","unstructured":"Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW. Dopamine D2 receptor density remains constant in treated Parkinson\u2019s disease. Ann Neurol 1986;19:487\u201392.","journal-title":"Ann Neurol"},{"key":"1202_CR40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(84)90238-3","volume":"99","author":"B Bokobza","year":"1984","unstructured":"Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson\u2019s disease and supranuclear palsy. Eur J Pharmacol 1984;99:167\u201375.","journal-title":"Eur J Pharmacol"},{"key":"1202_CR41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","volume":"318","author":"SJ Kish","year":"1988","unstructured":"Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876\u201380.","journal-title":"N Engl J Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-009-1202-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1202-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:01:48Z","timestamp":1558699308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-009-1202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,22]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s00259-009-1202-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,22]]}}}